Calla Lily Clinical Care awarded Innovate UK Grant to expand Callavid platform for vaginal microbiome health

Calla Lily Clinical Care, a clinical-stage women's health company, today announced it has been awarded a £700 k Innovate UK grant through its Growth Catalyst: Investor Partnerships program, which pairs grant funding with matched private investment. The grant supports a £1 M project, co-funded by Innovate UK, to adapt its patented Callavid® platform for the delivery of live biotherapeutic products (LBPs) and probiotics aimed at restoring vaginal microbiome health.

The new program, FLORA (Focused Lactobacillus Optimised Retention and Adhesion), will leverage the Company's proprietary intravaginal delivery platform to optimize the administration, transfer and retention of the beneficial Lactobacillus species, widely recognized for their role in maintaining a healthy vaginal microbiome.

Vaginal dysbiosis (VDy), an imbalance in the vaginal microbiome most commonly seen as bacterial vaginosis (BV), is associated with increased susceptibility to sexually transmitted infections including HPV and HIV, as well as pelvic inflammatory disease, miscarriage, preterm birth and poorer fertility and IVF outcomes. Despite increasing clinical understanding of the vaginal microbiome's importance in women's health, treatment of common dysbiosis-related conditions remains largely antibiotic-based and is associated with high recurrence rates, with BV alone recurring in ~58% of women within 12 months, contributing to the escalating :censored:6:cdd6bbaa89: challenge of antimicrobial resistance (AMR).

Targeted delivery of Lactobacilli represents a promising approach to microbiome restoration and to reducing repeated antibiotic treatment. Building on Callavid's development as a platform for optimized progesterone and antibiotic delivery, the FLORA project expands the device into this complementary biotherapeutic indication.

Calla Lily Clinical Care aims to deliver Callavid as the first over-the-counter product specifically designed to maximize probiotic transfer, retention, and colonization, while overcoming the leakage, dosing inconsistency and usability challenges associated with existing treatment formats. Alongside device development, the Company will also develop a proprietary laboratory model to evaluate bacterial colonization, generating data to inform future product development.

The award represents the third Innovate UK grant secured by Calla Lily Clinical Care and further strengthens its growing portfolio of translational women's health innovations. The Company's NIHR-funded FREEDOM trial is fully enrolled and now approaching completion, evaluating 400mg progesterone Callavid in patients diagnosed with luteal phase insufficiency - a condition associated with an increased risk of infertility and miscarriage. The Company also recently joined Wellcome Leap's $50M Focused Antibiotics program - a dedicated project transforming how antibiotics are delivered and directly addressing AMR public health objectives.

FLORA marks the third distinct application of the Callavid platform to secure independent, competitive funding: progesterone for threatened miscarriage (NIHR), targeted antibiotic delivery designed to spare the gut microbiome (Wellcome Leap), and now live biotherapeutics and probiotics for vaginal microbiome health (Innovate UK).

I Innovate UK has backed us from our earliest days and helped us build Callavid capital-efficiently. This third award takes us into an entirely new area. In under two years, the Callavid platform has won competitive funding for three different therapies: progesterone, antibiotics, and now live biotherapeutics and probiotics. The vaginal microbiome is one of the most exciting frontiers in women's health, but even the best bacteria will only help if they reach the right place and stay there. This is where Callavid can make a real difference for women."

Thang Vo-Ta, Co-Founder and CEO, Calla Lily Clinical Care

Dr Annalisa Jenkins OBE, Advisor to Calla Lily Clinical Care, former CEO of Dimension Therapeutics and Chair of Ori Biotech, added: "Over my career I have seen promising medicines fall short not because the science was wrong, but because getting them to the right place in the body proved harder than anyone expected. The vaginal microbiome is a clear example. The science behind live biotherapeutics is moving quickly, yet how they are delivered has had far less attention. If we can help women restore and maintain a healthy microbiome, we may improve her quality of life and reduce how often she will need repeated courses of antibiotics, lowering the potential for resistance that affects us all. Calla Lily has already taken Callavid from concept into the clinic, and this award gives the team the chance to tackle that delivery problem head on."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Comments are closed

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Severe long Covid associated with distinct oral and lung microbiomes